Related Experiment Video
Updated: Jul 5, 2026

Translaminar Autonomous System Model for the Modulation of Intraocular and Intracranial Pressure in Human Donor Posterior Segments
Published on: April 24, 2020
[Intraocular pressure related to uveitis]
U Pleyer1, P Ruokonen, C Heinz
1Universitäts-Augenklinik, Charité, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin. uwe.pleyer@charite.de
Inflammatory glaucoma, a complication of uveitis, presents significant treatment challenges. Managing elevated intraocular pressure (IOP) while controlling inflammation is crucial for preventing vision loss.
Area of Science:
- Ophthalmology
- Immunology
- Pathophysiology
Context:
- Uveitis causes blood-ocular barrier breakdown, leading to protein and cell influx.
- Inflammatory mediators like cytokines and chemokines contribute to elevated intraocular pressure (IOP).
- Steroid use for uveitis can also induce secondary IOP elevation.
Purpose:
- To review the mechanisms of inflammatory glaucoma.
- To discuss the challenges in managing uveitic glaucoma.
- To highlight the balance required between anti-inflammatory and IOP-lowering treatments.
Summary:
- Inflammatory glaucoma arises from intraocular inflammation, often uveitis.
- Pathogenesis involves trabecular meshwork obstruction, synechiae, and neovascularization.
- Elevated IOP management is complex due to inflammation and treatment side effects.
Impact:
- Effective management of uveitic glaucoma is essential to prevent irreversible vision loss.
- Current therapeutic strategies face challenges in balancing inflammation control and IOP reduction.
- Further research is needed for improved treatment outcomes in inflammatory glaucoma.
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Increased Intracranial Pressure ll: Pathophysiology
Increased Intracranial Pressure l: Introduction

